Article Details
Retrieved on: 2021-08-17 12:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company ... engineered to redirect host immune system to leukemic cells from patients ... Seven of these 8 with favorable responses had failed 2-4 prior lines of ...
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here